Navigation Links
LA BioMed investigator Dr. Christina Wang spearheads study on new male contraceptive gel
Date:6/28/2012

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) one of the leading biomedical research institutes in the country recently completed a study utilizing a new contraceptive gel that has the potential to be developed as a user controlled chemical birth control agent for males. The gel, which contains testosterone and a synthetic progestin called Nestorone, sharply lowers sperm counts in men with few side effects. The study conducted at LA BioMed and the University of Washington is funded by the National Institutes of Child Health and Human Development (NICHD).

Dr. Wang and her team, along with the team at the University of Washington, enrolled 99 men in a preliminary study of the drug combination. One third of them received a gel containing testosterone and a placebo, which was applied for six months. The remaining two thirds received a gel containing testosterone and one of the two concentrations of Nestorone. Fifty-six men completed at least 20 weeks of the study and adhered to the protocol.

The results of the study were reported at the recent Endocrine Society Meeting & Expo in Houston. Of the men receiving the drug combination, 88 to 89 percent achieved a sperm concentration of less than 1 million sperm per milliliter, while those receiving testosterone and the placebo achieved the same low sperm concentration in 23 percent of men. Depending on the dosage, there was a complete absence of sperm in 78 and 69 percent of the men receiving the drug combination, and in 23 percent of the men receiving testosterone and the placebo.

"Up until now, the responsibility for contraception has traditionally always been with the female," said Dr. Wang. "With these new contraceptive methods for males, the responsibility will be shared. While this gel has great potential and minimal side effects, it does warrant further study as a male contraceptive."

Dr. Wang is a renowned andrologist/endocrinologist and a world leader in efforts to develop a safe, effective and reversible hormonal male contraceptive. In addition to this study, she is also working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent by the National Institute of Child Health and Human Development.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
2. UMMS researcher Victor Ambros, Ph.D., named co-recipient of 2012 Janssen Award for Biomedical Research
3. UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
4. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. LA BioMed receives Grand Challenges Explorations grant
7. Biomedical researchers receive Hartwell Foundation awards
8. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
9. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
10. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
11. Pediatric kidney expert receives Young Investigator Award from American Transplant Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/26/2017)... ... 26, 2017 , ... Somnoware, a leading provider of digital ... its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device integration ... platform, initializing devices and importing studies are just one-click operations. This plugin streamlines ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... Peace Agreements being discussed by President Donald Trump and the rest of the world. ... speed up peace talks in the continuous battle between Israel and Palestine. The world’s ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
Breaking Medicine Technology: